A practical guide to Bayesian group sequential designs

被引:55
作者
Gsponer, Thomas [1 ]
Gerber, Florian [1 ]
Bornkamp, Bjoern [2 ]
Ohlssen, David [3 ]
Vandemeulebroecke, Marc [4 ]
Schmidli, Heinz [2 ]
机构
[1] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland
[2] Novartis Pharma AG, Stat Methodol, CH-4002 Basel, Switzerland
[3] Novartis Pharmaceut, Stat Methodol, E Hanover, NJ USA
[4] Novartis Pharma AG, Integrated Informat Sci, CH-4002 Basel, Switzerland
关键词
ENHANCING LESION COUNTS; CLINICAL-TRIAL; MULTIPLE-SCLEROSIS; IMPORTANT DIFFERENCE; SAMPLE-SIZE; DECISION; INFORMATION; CRITERION; POINT; MODEL;
D O I
10.1002/pst.1593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bayesian approaches to the monitoring of group sequential designs have two main advantages compared with classical group sequential designs: first, they facilitate implementation of interim success and futility criteria that are tailored to the subsequent decision making, and second, they allow inclusion of prior information on the treatment difference and on the control group. A general class of Bayesian group sequential designs is presented, where multiple criteria based on the posterior distribution can be defined to reflect clinically meaningful decision criteria on whether to stop or continue the trial at the interim analyses. To evaluate the frequentist operating characteristics of these designs, both simulation methods and numerical integration methods are proposed, as implemented in the corresponding R package gsbDesign. Normal approximations are used to allow fast calculation of these characteristics for various endpoints. The practical implementation of the approach is illustrated with several clinical trial examples from different phases of drug development, with various endpoints, and informative priors. Copyright © 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:71 / 80
页数:10
相关论文
共 41 条
[1]  
[Anonymous], 2010, Guidance for Industry and FDA Staff - Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems
[2]   INFERENCE AND DECISION IN CLINICAL-TRIALS [J].
ARMITAGE, P .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1989, 42 (04) :293-299
[3]  
Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
[4]   Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job? [J].
Carroll, Kevin J. .
PHARMACEUTICAL STATISTICS, 2009, 8 (04) :333-345
[5]   The role of the minimum clinically important difference and its impact on designing a trial [J].
Chuang-Stein, Christy ;
Kirby, Simon ;
Hirsch, Ian ;
Atkinson, Gary .
PHARMACEUTICAL STATISTICS, 2011, 10 (03) :250-256
[6]  
EMA, 2007, REFL PAP METH ISS CO
[7]   Frequentist evaluation of group sequential clinical trial designs [J].
Emerson, Scott S. ;
Kittelson, John M. ;
Gillen, Daniel L. .
STATISTICS IN MEDICINE, 2007, 26 (28) :5047-5080
[8]  
Food and Drug Administration, 2010, AD DES CLIN IN PRESS
[9]   Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials [J].
Friede, T. ;
Schmidli, H. .
METHODS OF INFORMATION IN MEDICINE, 2010, 49 (06) :618-624
[10]  
Gerber F, J STAT SOFTWAR UNPUB